amgen glp-1 obesity drug market potential 2025 Agonists Report 2025-2033, By Product, Molecule, and Geo Anti-Obesity Drugs Market Size to
Description
In 2005, exenatide was approved as a kind of GLP-1 receptor agonists (GLP-1RAs) for the clinical treatment of type 2 diabetes mellitus (T2DM) as the first international incretin drug [6]
In the second study, the authors reported a significant reduction of total testosterone and LH in only metformin group, while treatment with liraglutide led to a significant LH increase, without differences in FG score between the two groups [58]
These benefits were independent of baseline HbA1c and occurred without an increased risk of hypoglycemia [94]
Where the change has been felt most acutely is in the case of Weight Watchers a global company founded in 1963 that made many millions by offering weight-loss and diet programmes
doi: 10.23876/j.krcp.22.001 56 AstrupACarraroRFinerNHarperAKunesovaMLeanMEet al
